Bioceres Returns to Positive Adjusted EBITDA in Q4, But Full-Year Loss Widens
BIOX sits 44% above its 52-week low of $0.301.
Summary
Bioceres reported fiscal Q4 revenue of $55.9M, roughly flat YoY, with a net loss from continuing operations of $31.8M, an improvement from $54.4M a year ago. Adjusted EBITDA turned positive at $0.6M versus negative $9.6M in Q4 2025, driven by a 19% cut in SG&A. For the full year, revenue fell 18% to $238.3M and net loss widened to $54.4M from $49.1M, while Adjusted EBITDA declined to $25.5M from $28.9M. The company also recorded a $179.4M loss from discontinued operations related to the Pro Farm Group foreclosure. Management highlighted cost reductions and a strategic roadmap, but the balance sheet shows cash down to $11.2M from $32.7M and total equity collapsed to $64.1M from $295.2M. The earnings call is scheduled for September 15, 2026.
At the time of this announcement, BIOX was trading at $0.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.1M. The 52-week trading range was $0.30 to $2.19. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.